Roche is the world’s largest biotech company and a leader in in-vitro diagnostics. The company is known for its strong oncology franchise (Herceptin, Avastin, Tecentriq) and diagnostics leadership through Roche Diagnostics.
Oncology, Diagnostics, Immunology, Neuroscience
5-year financial trajectory
Business segment breakdown
Key product revenue comparison
Geographic revenue split
| Product | Indication | Revenue |
|---|---|---|
| Tecentriq (atezolizumab) | Oncology | $4.0B |
| Ocrevus (ocrelizumab) | MS | $6.4B |
| Hemlibra (emicizumab) | Hemophilia A | $4.5B |
| Perjeta (pertuzumab) | HER2+ breast cancer | $4.5B |
| Actemra (tocilizumab) | Immunology | $3.5B |
| Evrysdi (risdiplam) | SMA | $1.4B |
Roche is the #3 pharma company and #1 in diagnostics. Highest R&D spend ratio in the industry (28%). Bispecific antibody platform (Lunsumio, Glofitamab) represents next oncology growth wave.
Revenue projected to recover to $55-58B by 2026 as COVID diagnostics normalize and bispecific antibody launches accelerate. Ocrevus and Hemlibra remain strong growth drivers in neurology and rare diseases.
Roche 2023 Annual Report. Revenue and financial data from SEC filings (Form 10-K/20-F). Pipeline data from company R&D presentations and ClinicalTrials.gov. Market analysis by Medifirm Intelledge Global.